Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00702-25 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Yichen Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Center, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins, Lung, Siderophores. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
HRS-8427, a novel siderophore cephalosporin antibiotic, is under development for treating Gram-negative infections. This study evaluated the intrapulmonary penetration and pharmacokinetic (PK) profile of HRS-8427 injection following single and multiple dose administrations in healthy Chinese subjects. A single-center, randomized, open-label Phase 1 trial enrolled 38 subjects, with 35 completing the study. In the single-dose group, subjects received a 1,500 mg intravenous infusion of HRS-8427 over 2 h. In the multiple-dose group, subjects were administered 2,000 mg of HRS-8427 intravenously every 8 h for four consecutive doses, each infused over 2 h. Bronchoalveolar lavage (BAL) was conducted to collect epithelial lining fluid (ELF) and alveolar macrophage (AM) specimens. PK analysis demonstrated a maximum plasma concentration ( C max ) of 176 µg/mL and an area under the time-concentration curve from time zero to time infinity (AUC 0–∞ ) of 942 h·μg/mL following the single 1,500 mg dose. After multiple 2,000 mg dosing, the C max increased to 262 µg/mlL with a corresponding AUC 0–∞ of 1,640 h·μg/mL. The ELF-to-plasma concentration ratio ( C ELF / C plasma ) exhibited a time-dependent increase, reaching 12.2% at 8 h post-final dose. Intracellular accumulation in AM remained minimal (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Center, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China.
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
- Department of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Hunan Key Laboratory of Organ Fibrosis, Changsha, Hunan, China.
ORCID-Profile: Yuanyuan Huang, Jie Huang, Guoping Yang
Förderung
- Natural Science Foundation of Hunan Province
Zitieren
APA
Cao, Y., Huang, Y., Xie, J., Wu, Q., Yang, S., Yang, X., Huang, J., Liu, J., Meng, J., & Yang, G. (2025). Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00702-25
Vancouver
Cao Y, Huang Y, Xie J, Wu Q, Yang S, Yang X, et al. Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00702-25
BibTeX
@article{Cao2025,
author = {Cao, Yichen and Huang, Yuanyuan and Xie, Jinlian and Wu, Qian and Yang, Shuang and Yang, Xiaoyan and Huang, Jie and Liu, Jinlong and Meng, Jie and Yang, Guoping},
title = {Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00702-25}
}
EUVIMED